Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334074 · ClinicalTrials.gov registry record · Phase 2
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
A Phase 2 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00334074 is a Phase 2 study that has completed, run by Baylor Research Institute. The registered enrollment target is 30 participants.
The verdict
NCT00334074, a Phase 2 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.
Interventions
- DRUG Clofarabine and Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334074
The ClinicalTrials.gov registry entry for NCT00334074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clofarabine and Cytarabine is the first listed.
NCT00334074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00334074 about?
NCT00334074 is a clinical study titled "Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS". The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.
What is the current status of trial NCT00334074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-08. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00334074?
The interventions under investigation include: Clofarabine and Cytarabine (DRUG).
Who is sponsoring clinical trial NCT00334074?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.